Susan Hasty, Publisher
Table of Contents . . . August 16th, 1999Non-Subscriber - Summaries Only
Disease Markers - Portal Lymphadenopathy Suggests Liver Damage in HCV+
Research & Development - NIH Announces 8-Year Hepatitis Therapy Study
Risk Factors - IFN Therapy Reduces Liver Cancer in HCV Patients
Therapy (HCV) - Ribavirin/IFN-(alpha) Shows Promise in Initial Nonresponders
Transmission (HCV) - Hepatitis Spread Through Endoscopes Could be Eliminated
Dendritic Cells - Researchers Advance Way To Stimulate Human Immune System
Industry News (HBV Treatment) - Zeffix Approved in the European Union
Disease Associations - "Severe Atypical Psoriatic Erythroderma Precipitated by Acute Hepatitis B Infection."
Transmission (HCV) - "Vaginal Shedding of Hepatitis C Virus."
Blood Safety (HCV Contamination) - "High-Throughput Extraction, Amplification, and Detection (HEAD) of HCV-RNA in Individual Blood Donations."
HCV-Induced Hepatocellular Carcinoma - "Risk Factors for Development of Hepatocellular Carcinoma among Australians with Hepatitis C: A Case-Control Study."
Interferon Therapy - "Enhancing the Response to Interferon-alpha."
Interferon Therapy (HBV) - "Retreatment of Chronic Hepatitis B e Antigen-Positive Patients with Recombinant Interferon alfa-2a."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.